Stocks · News reference

Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response

Sep 1, 2026, 10:15 AMBenzinga Newsdesk

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NTRA

Source: benzinga
Observed: Sep 1, 2026, 10:15 AM
Checked: Sep 1, 2026, 10:15 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 27, 2026, 10:08 AMBenzinga Newsdesk
Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
NTRA
BenzingaAug 13, 2026, 7:50 PMBenzinga Newsdesk
Citigroup Maintains Buy on Natera, Raises Price Target to $365
Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.
NTRA
BenzingaAug 12, 2026, 4:26 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5
Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $249 to $363.5.
NTRA

Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response

Connected Markets

Related Headlines

Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates

Citigroup Maintains Buy on Natera, Raises Price Target to $365

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5